Low Dose Naltrexone & Autoimmune Conditions

There is growing recognition in the scientific community that autoimmune diseases result from immunodeficiency, which disturbs the ability of the immune system to distinguish "self" from "non-self". The normalization of the immune system induced by LDN makes it an obvious candidate for a treatment plan in such diseases.The experience of people who have autoimmune diseases and who have begun LDN treatment has been remarkable. Patients with diagnoses such as systemic lupus, rheumatoid arthritis, Behcet's syndrome, Wegener's granulomatosis, bullous pemphigoid, psoriasis, and Crohn's disease have all benefited. Because LDN clearly halts progression in multiple sclerosis, its use has been more recently extended to other neurodegenerative diseases, such as Parkinson's disease and amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) whose etiology remains unknown but for which there is suggestive evidence of a possible autoimmune mechanism.

  • Immunosuppressive Drugs
  • Ulcerative colitis

Related Conference of Low Dose Naltrexone & Autoimmune Conditions

March 04-05, 2019

10th Molecular Immunology & Immunogenetics Congress

Barcelona, Spain
March 18-19, 2019

11th Global Summit on Immunology and Cell Biology

Sydney, Australia
March 18-19, 2019

13th International Congress on Autoimmunity

Brisbane, Australia
April 15-18, 2019

Annual Immunology Conference 2019

Savannah, USA
June 13-14, 2019 |

10th European Immunology Conference

Berlin, Germany
July 24-25, 2019

11th World Congress and Expo on Immunology

Vancouver, Canada
July 29-30 2019

6th International Conference on Parasitology & Microbiology

Amsterdam, Netherlands
October 21-22, 2019

12th Annual Congress on Immunology & Immunogenetics

Rome, Italy
November 22-23, 2019 |

World Conference on Vaccine and Immunology

Dubai, UAE

Low Dose Naltrexone & Autoimmune Conditions Conference Speakers

Recommended Sessions

Related Journals

Are you interested in